1[1]Pickup JC, Mattock MB, Chusney GD, et al. NIDDM as a disease of the innate immune system: association of the acutephase reactants and interlerkin 6 with metabolic syndrome X. Diabetologia 1997;40:1286.
2[2]Stouthard JM, Romijn JA, Van der Poll T, et al. Endocrinologic and metabolic effects of interleukin-6 in humans. Am J Physiol 1995;268:E813.
3[3]Fermandez-Real JM, Broch M, Vendrell J, et al. Insulin resistance, inflammation and serum fatty acid composition. Diabetes Care 2003;26:1362.
4[4]Nelson TL, Hickey MS. Acute changes in dietary omega-3 fatty acid intake lowers soluble interleukin-6 receptor in healthy adult normal weight and overweight males. Cytokine 2004 Jun 7 ;26(5): 195.
5[5]Fernandez-Real JM, Vayreda M, Richart C, et al. Circulating jnterleukin 6 levels, blood pressure and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 2001 ;86:1154.
6[6]Straub RH, Hense HW, Andus J, et al. Hormaone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population-based study. J Clin Wndocrinol Metab 2000; 85:1340.
7[7]Wallenius V, Wallenius K, Ahren B, et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 2002; 8:75.
8[8]Fernandez-Real JM, Broch M, Vendrell J, et al. Interleukin 6 and insulin sensitivity. Diabetes 2000;49:517.
9[9]Stephens JW, Hurel SJ, Cooper JA, et al. A common functional variant in the interleukin-6 gene is associated with increased body mass ndex in subjects with type 2 diabetes mellitus. Mol Genet Metab 2004 Jun;8(2):180.
10[10]Southern C, Schulster D, Green IC. Inhibition of insulin secretion from rat islets of Langerhans by interleukin-6. Biochem J 1990;272:243.
